



Merging
& Pharma
Biotech

●●●●●● **Bi**● PHARMACEUTIQUES

BioPHARM



Pipeline expansion, renewed interest from big pharma in forging multiple alliances with biotech companies, IPO preparations... at a time when biotech is bubbling again and with the frontier between pharma and biotech becoming increasingly blurred, BioPharmaceutiques offers you the opportunity to capitalize on its experience via a new publication – BioPharmaceutiques.

BioPharmaceutiques offers you access to the latest biotech information with a resolutely European angle and interprets the sector's news from a pharma perspective.

Every week, BioPharmaceutiques delivers high-quality content to your e-mail inbox:

- biotech-biotech and pharma-biotech alliances and M&A activity
- the latest IPOs
- the latest milestones and investment rounds
- an overview of the most recent biotech start-ups
- clinical trial launches
- the latest developments in the field of biotech drugs
- news on European directives and regulations
- a "movers and shakers" section, with the latest appointments

Rather than being just another weekly newsletter, BioPharmaceutiques also seeks to provide sector stakeholders (the pharma industry, biotech companies, CROs, investors, funding bodies and institutional players) with a rapidly assimilated summary of who is doing what and with whom.

Thanks to a dedicated website with weekly updates from the latest editions of BioPharmaceutiques, subscribers will have access to summary tables providing molecule, company and disease-specific overviews of the latest negotiations, alliances and developments.




PHARMACEUTICALS

OUR WEEKLY NEWSLETTER

Biotech news at a glance

Delivered weekly to your inbox, BiPharmaceutiques focuses in on the latest biotech news. Your time is precious, so you need a tool which can identify the sector's key information - BiPharmaceutiques gives you immediate access to a list of article headlines

If something catches your eye and you want to find out more, just click on the title's hyperlink and access the full content.



BiPHARMACEUTIQUES

HOME WHO WE ARE ARCHIVES SUMMARY TABLES

Merging Pharma & Biotech

Issue 29 - June 28th 2007

Summary tables

- Agreements
- Clinical Studies
- Fundraisings
- Acquisitions

Editorial

- In the land of the biosimilars**

Europe is leading the race to make the first biosimilars available to patients, and is steadily adding to the portfolio of authorisations and positive opinions granted in the EU. Meanwhile, across the Atlantic, these same products (referred to as "follow-on" biologics) are not even in game - although some may at last get out of the starting blocks, where they have been trapped by the USA's regulatory vacuum...

Despite the fact that this shortcoming has been identified and debated several times (particularly by the Democrats), a legal framework is now taking shape, now that the Senate's Health Education, Labor and Pensions Committee has cleared draft legislation sponsored by both Democratic and Republican politicians. However, with the text yet to go before the House of Representatives, it has already attracted criticism from many sides. The Pharmaceutical Association has objected to the bill's 12 years of exclusion before a biosimilar version can be marketed. Biotech companies will probably judge that the demonstration of biosimilarity based on analytical & animal data, and at least one clinical study is insufficient, and that replacement by a follow-on biologic should not risk endangering the patient's health.

Browse by date

September, 2007

Mon	Tue	Wed	Thu	Fri	Sat	Sun
				1	2	
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Select date

Summary tables

Agreements

Clinical Studies

Fundraisings

Acquisitions

DRILLING DOWN: OUR INTERACTIVE SUMMARY TABLES

"WHO IS DOING WHAT AND WITH WHOM IN THE EUROPEAN BIOTECH SECTOR?"

Based on a template enabling you to sort information by company, development phase, compound or disease. Our summary tables enable you to answer these key questions and access synoptic data.

Featured summary tables:

- Agreements ●
- Clinical Studies ●
- Fundraisings ●
- Acquisitions ●



A subscription format which is clear and straightforward -
just like the concept behind Bi●Pharmaceutiques

A single corporate subscription for your whole company

Offer all your employees access to Bi●Pharmaceutiques with no restrictions on numbers and in full compliance with intellectual property rules.

When subscribing, just send us a list of your company's subscriber names. As soon as your subscription has been processed, you will automatically receive the Bi●Pharmaceutiques newsletter. To access the content and resources on the Bi●Pharmaceutiques website, you will have to activate your account during your first visit.

SUBSCRIPTION RATES FOR 2007

- Pharmaceutical companies: €3,000 + VAT per annum
- Biotech companies with a turnover > €20 million:
€3,000 + VAT per annum
- Biotech companies with a turnover < €20 million and other subscribers:
€1,000 + VAT per annum

●●●●● **Bi●**PHARMACEUTIQUES

BioPharmaceutiques

Publisher: PR Editions

22, avenue d'Eylau, F-75116 Paris, France

Subscriptions: +33 144 058 300

info@pharmaceutiques.com

www.biopharmaceutiques.com

Your tariff:

- Pharmaceutical companies: €3,000 + VAT per annum
- Biotech companies (turnover > €20 million): €3,000 + VAT per annum
- Biotech companies (turnover < €20 million): €1,000 + VAT per annum
- Other category, please specify: €1,000 + VAT per annum

This corporate subscription enables you to provide all your employees with access to the BiPharmaceutiques newsletter.

On receipt of this document, we will contact you in order to define the distribution mode.

Subscription manager:

Family name: First name:

Company/organization:

Job title:

Street address:

Town/city: Postcode/zip code:

State (if applicable): Country:

Tel.: E-mail:

Billing address:

Company/organization:

Department:

Contact person:

Street address:

Town/city: Postcode/zip code:

State (if applicable): Country:

Signature

Date

Subscription information:

Pharmaceutiques magazine

Tel.: +33 144 058 302 – Fax: +33 144 058 318

info@pharmaceutiques.com

www.biopharmaceutiques.com